JANX News and Press, Janux Therapeutics Inc. From 12/13/23

2023-12-13 07:12:15 ET Summary Janux Therapeutics is a biotech focused on developing novel immunotherapeutic approaches for cancer patients. Their lead candidate, JANX007, is a tumor-activated T-cell engager that targets PSMA in prostate cancer. Janux also has two other molecu...

2023-11-16 03:13:26 ET More on Janux Therapeutics Seeking Alpha’s Quant Rating on Janux Therapeutics Historical earnings data for Janux Therapeutics Financial information for Janux Therapeutics For further details see: Janux Therapeutics up ~4%, CF...

2023-11-08 09:20:03 ET More on Janux Therapeutics Seeking Alpha’s Quant Rating on Janux Therapeutics Historical earnings data for Janux Therapeutics For further details see: Janux Therapeutics GAAP EPS of -$0.25

Janux Therapeutics Inc. (JANX) is expected to report $-0.46 for Q3 2023

Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer Enrollment ongoing for EGFR-TRACTr (JANX008) in solid tumors Update on clinical programs expected in 2024 $349.7 million in cash, cash equivalents, and short-term investments at end of third quarter 2023 ...

2023-08-09 13:06:36 ET Janux Therapeutics press release ( NASDAQ: JANX ): Q2 GAAP EPS of -$0.42. Revenue of $1.05M (-55.5% Y/Y). For further details see: Janux Therapeutics GAAP EPS of -$0.42, revenue of $1.05M

Presented positive interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer Management team bolstered with key appointment $303.3 million in cash, cash equivalents, and short-term investments at end of second quarter 2023 In July, further strengthened...

2023-07-25 11:56:09 ET Summary Janux Therapeutics, Inc. is a small company with a deal from Merck & Co., Inc. and some solid early data. They are loaded with cash and have a long runway. Janux Therapeutics generates considerable smart money interest. Janux Ther...

2023-07-24 10:09:58 ET Gainers: Armata Pharmaceuticals ( ARMP ) +19% . Janux Therapeutics ( JANX ) +11% . Amylyx Pharmaceuticals ( AMLX ) +8% . Coherus BioSciences ( CHRS ) +7% . Nuwellis ( NUWE ) +7% . Losers: Kodiak...

2023-07-17 08:59:08 ET Biopharmaceutical company Janux Therapeutics ( NASDAQ: JANX ) said on Monday that it has priced an ~$60M underwritten offering of 4.2M shares and pre-funded warrants to purchase 583.45K shares. The shares are being sold at $12.46 per share and the pre-fu...